MADRID, May 9, 2011 /PRNewswire-FirstCall/ -- Elsevier (http://www.elsevier.com), the leading global publisher ofscientific, technical, and medical information products and services, announced today the acquisition of Fisterra.com, an award winning, widely used e-clinical reference solution in Spain. Fisterra was launched in 2002
Fisterra.com provides access to Fisterrae, an advanced e-clinical reference solution that integrates support resources for health professionals in a local language platform. Fisterrae is written by doctors and pharmacists and is kept permanently up to date by following medical journals, reviews by the Cochrane Library and the most important databases of clinical practice guidelines.
"Fisterra has been a trusted and integral partner to the Spanish medical community so we're proud of this acquisition," said Claudia Pickholz, Managing Director, Elsevier Spain. "By combining Fisterra's content with Elsevier's Spanish and English language online reference materials we can create a powerful e-clinical reference solution, provide useful and high quality content for clinical decision making and add to our range of content and support services for medical students and professionals."
Fisterra.com solutions include: clinical guides and protocols; a clinical drug database with dosage calculators; a vaccination tool; electronic continuing medical education content; and patient handouts. A mobile app suitable for point of care contexts is also in development.
"With Elsevier's broad experience in content creation and review, Fisterra.com will receive new consultation assets that satisfy the needs of its professional customers," said Arturo Louro, one of Fisterra.com's founders who will continue to consult for the site and serve on the product's new advisor board.
The website will add to Elsevier's electronic services supported by the most distinguished local authors, translations of major international references, information and first-level knowledge to individuals and groups engaged in quality health practice and research.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com/) and Cell (http://www.cell.com/), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect (http://www.sciencedirect.com/), SciVerse Scopus (http://www.scopus.com/home.url), Reaxys (https://www.reaxys.com/info/), MD Consult (http://www.mdconsult.com/php/241547652-53/homepage) and Nursing Consult ( http://confidenceconnected.com/login/consult?env=PROD&URI=/nursing/index), which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review (http://www.medai.com/), which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media Contact Tom Reller VP, Corporate Relations, Elsevier T.Reller@elsevier.com +1-215-239-3508
Subscribe to our Free Newsletters!
Fallot's tetralogy is a rare and complex birth defect of the heart. Babies born with this condition ...
Bubonic plague is an infectious disease caused by the bacteria Yersinia pestis present in rodents ...
Steroids are miracle drugs but have to be used with caution. Some steroids are illegal to use, ...View All